A Comparative Analysis of Different Prescription Points in High Dose Rate Brachytherapy of Cervical Cancer

Document Type : Original Paper


1 Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, India

2 Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Vibhuti Khand Gomti Nagar, Lucknow -226010 India

3 Advance Cancer Centre, Bathinda, Punjab

4 Department of Radiation Oncology, Govt. Medical College, Patiala, India


Introduction: The dose prescription point in high dose rate (HDR) intracavitory brachytherapy (ICBT) of cervical cancer is Manchester point A but the localization of this point has a wider variation. To minimize these variations, the American Brachytherapy Society (ABS) introduced a new definition of point A and named it as point H. In this study, these two points have been compared in terms of dosimetric parameters.
Material and Methods: Twenty HDR ICBT of cervical cancer patients were retrospectively evaluated with Manchester point A and ABS point H. Target volume covered by prescribed dose (TV), dose to 2cc (D2cc) of the bladder and rectum were noted for both points. Statistical analysis using a two-tailed paired t-test was performed to compare dosimetric parameters of both the points of prescription. The maximum value, minimum value, and mean ± standard deviation along with the p value have been noted.
Results: On average, point H was 4.0mm ± 6.4mm shifted (superior/inferior) from point A, along the tandem direction. The average TV when the prescription was done at point H (TVH) was 33.7cc ± 10.1cc which was higher than the average TV when the prescription was done at point A (TVA) of 33.3cc ± 9.4 cc.D2cc increased from 63% ± 23% to 68% ± 24% for the rectum and 52% ± 18% to 56% ± 20% for the bladder when the prescription point changed from A to H.
Conclusion: As observed, average TV, D2cc of the bladder, and rectum were higher in the case of point H prescription plan (PH) as compared with point A prescription plan (PA). The dose difference between PH and PA was found to be statistically significant, so careful consideration is needed to implementation of new point H in clinical practice.


Main Subjects

  1. Bandyopadhyay A, Basu P, Roy K, Das S, Banerjee S. Treatment of locally advanced carcinoma cervix with special emphasis on brachytherapy: A practice pattern survey among young radiation oncologist of India. South Asian Journal of Cancer. 2018 Oct;7(04):231-5.
  2. Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations Committee. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012 Jan 1;11(1):33-46.
  3. Viswanathan AN, Beriwal S, Jennifer F, Demanes DJ, Gaffney D, Hansen J, Jones E, Kirisits C, Thomadsen B, Erickson B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012 Jan 1;11(1):47-52.
  4. Lee LJ, Das IJ, Higgins SA, Jhingran A, Small Jr W, Thomadsen B, Viswanathan AN, Wolfson A, Eifel P. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy. Brachytherapy. 2012 Jan 1;11(1):53-7.
  5. Anderson J, Huang Y, Kim Y. Dosimetric impact of point A definition on high-dose-rate brachytherapy for cervical cancer: evaluations on conventional point A and MRI-guided, conformal plans. Journal of contemporary brachytherapy. 2012 Dec;4(4):241.
  6. Zhang M, Chen T, Kim LH, Nelson C, Gabel M, Narra V, Haffty B, Yue NJ. Three-dimensional dosimetric considerations from different point A definitions in cervical cancer low-dose-rate brachytherapy. Journal of Contemporary Brachytherapy. 2013 Dec;5(4):222.
  7. Tyagi K, Mukundan H, Mukherjee D et al. Non isocentric film-based intracavitary brachytherapy planning in cervical cancer: a retrospective dosimetric analysis with CT planning. J Contemp Brachytherapy. 2012 sep; 4: 129-34.
  8. Opfermann KJ, Wahlquist  A, Watkins J et al. Impact of point A asymmetry on local control and survival for low dose-rate (LDR) brachytherapy in cervical cancer. J Contemp Brachytherapy. 2012 Mar; 1: 3-7.
  9. Srivastava S, Painuly NK, Mishra SP, Srivastava K, Singh N, Bhatt ML. Effect of different definitions of prescription point “A” in high dose rate brachytherapy for cervical cancer. Journal of Cancer Research and Therapeutics. 2019 Oct 1;15(6):1365.
  10. Mahantshetty U, Poetter R, Beriwal S, Grover S, Lavanya G, Rai B, et al. IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer. Radiother Oncol. 2021 Jul; 160: 273-84.
  11. Kim Y, Huang Y, Bayouth JE, Flynn RT, Bhatia SK, Jacobson GM, et al. Dosimetric consequences of the prescription point H of ABS recommendation in the era of MRI guided brachytherapy for cervical cancer: based on GYN GEC-ESTRO recommendations of MRI guided brachytherapy. International Journal of Radiation Oncology, Biology, Physics. 2008 Sep 1;72(1):S586-7.
  12. Tod M, Meredith WJ. Treatment of cancer of the cervix uteri—a revised “Manchester method”. The British journal of radiology. 1953 May;26(305):252-7.